Stomatitis is inflammation of the oral mucosa involving tissues of the mouth or lips. It may arise from infection, irritants, trauma, medications, systemic disease, or cancer therapy and can cause painful oral lesions.
FDA approves AstraZeneca and Daiichi Sankyo's Datroway for first-line TNBC patients not eligible for PD-1/L1 inhibitors, based on Phase III TROPION-Breast02 data showing a 21% reduction in risk of death versus chemotherapy.
Sacituzumab tirumotecan demonstrated a median overall survival of 20.0 months versus 13.5 months with docetaxel in pretreated EGFR-mutated NSCLC patients. The phase 2 OptiTROP-Lung03 study showed a hazard ratio of 0.63 for overall survival benefit with the TROP2-directed antibody-drug conjugate.
New research from the University of Missouri-Columbia reveals that targeted cancer therapies, including tyrosine kinase inhibitors, antibody-drug conjugates, and CAR-T cell therapies, cause distinct patterns of gastrointestinal injury that are often underrecognized.
Phase III trial demonstrates belzutifan plus lenvatinib significantly improved progression-free survival versus cabozantinib in previously treated renal cell carcinoma patients, while neoadjuvant studies show promise for locally advanced disease.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07543978 |
Traditional Chinese Medicine for the Prevention of Radiotherapy-Induced Oral Mucositis (RTOM) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07506018 |
MucoLock™ for Treatment of Stomatitis |
RECRUITING | NA |
| NCT07400328 |
Amimestrocel Injection for Preventing Severe Oral Mucositis in HSCT Patients |
RECRUITING | PHASE2 |
| NCT07357597 |
An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer. |
NOT_YET_RECRUITING | PHASE4 |
| NCT07322666 |
Non-Thermal Plasma vs. Low-Level Laser Therapy for Recurrent Oral Ulcers |
COMPLETED | NA |
| NCT06532279 |
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer |
RECRUITING | PHASE2 |
| NCT06071637 |
Low Power Laser Therapy As Prevention Of Oral Mucositis And Oropharyngeal Pain In Patients Undergoing Allogenetic HSCT |
RECRUITING | PHASE3 |
| NCT05878405 |
Methylene Blue Mouthwash for the Treatment of Oral Mucositis Pain in Patients With Cancer |
COMPLETED | PHASE3 |
| NCT05323058 |
The Use of Tulsi Extract for The Management of Oral Mucositis in Head & Neck Cancer Patients Undergoing Radiotherapy |
UNKNOWN | PHASE2 |
| NCT05010928 |
Using Tea-based Mouthwash Relieve Stomatitis and Oral Ulcers |
UNKNOWN | PHASE2 |
